Consumer >> Analyst Interviews >> April 5, 2019

Biosynthetic Cannabinoids Poised to Be a Big Disruptor in the Cannabis Space

Kideckel, David
David Kideckel is a Managing Director and Senior Equity Research Analyst at AltaCorp Capital Inc., heading the firm’s life sciences research franchise. Prior to joining AltaCorp Capital, Dr. Kideckel was at another leading independent investment dealer, in his role as Director of Healthcare & Biotechnology, Institutional Equity Research. Dr. Kideckel is a seasoned industry executive, having spent nearly 15 years in international pharmaceutical, biotechnology and medical device companies where he held executive roles in sales, marketing, medical affairs and international business development. Dr. Kideckel holds a Ph.D. and MBA from the University of Toronto’s Institute of Medical Science and Rotman School of Management, respectively. He is a university Gold Medalist and a recipient of the Canadian Institutes of Health Research Science to Business Award. Profile
Word count: 2,953

TWST: If you wouldn't mind, let’s start with an introduction to your coverage universe and what you think differentiates your research from that of your